KIR2DL1

KIR2DL1 Overview

English Name	Killer cell immunoglobulin-like receptor 2DL1	Approved Drugs	0
Drugs in Clinical Trials	1	Target Synonym	KIR2DL1，NKAT-1，NKAT1，MHC class I NK cell receptor，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 1，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 1，P58 Natural Killer Cell Receptor Clones CL-42/47.11，P58 Killer Cell Inhibitory Receptor KIR-K64，Natural Killer-Associated Transcript 1，P58.1 MHC Class-I-Specific NK Receptor，CD158 Antigen-Like Family Member A，P58 NK Receptor CL-42/47.11，CD158A，Killer Cell Immunoglobulin-Like Receptor 2DL1，P58 NK Cell Inhibitory Receptor NKR-K6，Killer Inhibitory Receptor 2-2-1，KIR2DL Protein，CD158a Antigen，KIR2DL1/3DL2，KIR-K64，KIR221，P58.1，NKAT，Receptors， KIR2DL1，Cl-42
Highest Development Stage	Phase 2 Clinical

English Name	Killer cell immunoglobulin-like receptor 2DL1
Target Synonym	KIR2DL1，NKAT-1，NKAT1，MHC class I NK cell receptor，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 1，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 1，P58 Natural Killer Cell Receptor Clones CL-42/47.11，P58 Killer Cell Inhibitory Receptor KIR-K64，Natural Killer-Associated Transcript 1，P58.1 MHC Class-I-Specific NK Receptor，CD158 Antigen-Like Family Member A，P58 NK Receptor CL-42/47.11，CD158A，Killer Cell Immunoglobulin-Like Receptor 2DL1，P58 NK Cell Inhibitory Receptor NKR-K6，Killer Inhibitory Receptor 2-2-1，KIR2DL Protein，CD158a Antigen，KIR2DL1/3DL2，KIR-K64，KIR221，P58.1，NKAT，Receptors， KIR2DL1，Cl-42
Approved Drugs	0
Drugs in Clinical Trials	1
Highest Development Stage	Phase 2 Clinical

KIR2DL1 Product List

Product Category
Protein (1)
Product Status
Launched (1)
Species
Human (1)
Tag
Fc Tag (1)
Conjugate
Unconjugated (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature	Order Now
KI1-H5255	Human	HEK293	Human KIR2DL1 / CD158a / NKAT-1 Protein, Fc Tag				Add to Cart

Total: 1

KIR2DL1 Background

Killer cell immunoglobulin-like receptor 2DL1(KIR2DL1), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. Regulation of NK cell activity is mediated through killer-cell immunoglobulin-like receptors (KIR) ability to recognize human leukocyte antigen (HLA) class I molecules as ligands. Interaction of KIR and HLA is implicated in viral infections, autoimmunity, and reproduction and there is growing evidence of the coevolution of these two independently segregating gene families. Association of KIR2DL1 with β-arrestin 2 mediated recruitment of the tyrosine phosphatases SHP-1 and SHP-2 to KIR2DL1 and facilitated downstream inhibitory signaling.

KIR2DL1 Synonyms

CD158a

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Lirilumab	IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015	Phase 2 Clinical	Novo Nordisk A/S	Bone Marrow Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Smoldering Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms	Details